Flores-Estrada JJ, Pinto-García LJ, Nájera-García N, Marché-Fernández OA, Cáceres-Carranza FJ

Idioma: Inglés [English version]
Referencias bibliográficas: 30
Paginas: 51-57
Archivo PDF: 443.53 Kb.

RESUMEN

La enfermedad por hígado graso no alcohólico (NAFLD, por sus siglas en inglés), asociada con la obesidad y la diabetes tipo 2, afecta a casi mil millones de personas a nivel mundial, con una prevalencia en aumento debido a tanto mejoras en los métodos diagnósticos como al incremento en su incidencia. En México, la prevalencia de la NAFLD podría superar el 50%. Un estudio realizado en 505 adultos jóvenes encontró que el 47% estaba en riesgo de esteatohepatitis no alcohólica (NASH, por sus siglas en inglés) y que 67.8% presentaba rigidez hepática anormal o un diagnóstico confirmado de NASH. El manejo de la NAFLD requiere un enfoque integral, desde cambios en el estilo de vida en las etapas iniciales hasta tratamientos farmacológicos dirigidos para fibrosis o cirrosis avanzadas. La metformina, un medicamento ampliamente utilizado para la diabetes, muestra potencial en la NAFLD al mejorar los marcadores de daño hepático y la resistencia a la insulina, y podría reducir el riesgo de carcinoma hepatocelular, aunque la evidencia sobre mejoras histológicas significativas en el hígado es limitada. Este artículo analiza el papel de la metformina en el tratamiento de la NAFLD, con énfasis en su posible impacto en México y a nivel global.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. J Intern Med. 2020; 287 (6): 711-722. doi: 10.1111/joim.13035.

2. Sepulveda-Villegas M, Roman S, Rivera-Iñiguez I, Ojeda-Granados C, Gonzalez-Aldaco K, Torres-Reyes LA et al. High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. PLoS One. 2019; 14 (1): e0208926. doi: 10.1371/journal.pone.0208926.

3. Schattenberg JM, Bergheim I. Nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD). Nutrients. 2019; 11 (3): 588. doi: 10.3390/nu11030588.

4. Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021; 17 (1): 23-28. 2021. doi: 10.1002/cld.1045.

5. Cheng Z, Chu H, Zhu Q, Yang L. Ferroptosis in non-alcoholic liver disease: Molecular mechanisms and therapeutic implications. Front Nutr. 2023; 10: 1090338. 2023. doi: 10.3389/fnut.2023.1090338.

6. Zhou J, Massey S, Story D, Li L. Metformin: an old drug with new applications. Int J Mol Sci. 2018; 19 (10): 2863. doi: 10.3390/ijms19102863.

7. Huang Y, Wang X, Yan C, Li C, Zhang L, Zhang L et al. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022; 101 (43): e31437. doi: 10.1097/MD.0000000000031437.

8. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305 (16): 1659-1668. doi: 10.1001/jama.2011.520.

9. Zhang Y, Wang H, Xiao H. Metformin actions on the liver: protection mechanisms emerging in hepatocytes and immune cells against NASH-Related HCC. Int J Mol Sci. 2021; 22 (9): 5016. doi: 10.3390/ijms22095016.

10. Ganguli S, DeLeeuw P, Satapathy SK. A review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepat Med. 2019; 11: 159-178. doi: 10.2147/HMER.S188991.

11. Cetin M, Sahin S. Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride. Drug Deliv. 2016; 23 (8): 2796-2805. doi: 10.3109/10717544.2015.1089957.

12. Zaks I, Getter T, Gruzman A. Activators of AMPK: not just for type ii diabetes. Future Medicinal Chemistry 2014; 6 (11): 1325-1353. Available in: https://doi.org/10.4155/fmc.14.74

13. Futatsugi A, Masuo Y, Kawabata S, Nakamichi N, Kato Y. L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides. J Pharm Pharmacol. 2016; 68 (9): 1160-1169. doi: 10.1111/jphp.12574.

14. Haak T. Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2015; 8: 1-6. doi: 10.4137/CMED.S10360.

15. Ursini F, Russo E, Pellino G, D'Angelo S, Chiaravalloti A, De Sarro G, Manfredini R et al. Metformin and autoimmunity: a "new deal" of an old drug. Front Immunol. 2018; 9: 1236. doi: 10.3389/fimmu.2018.01236.

16. Chai SC, Wright WC, Chen T. Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer. Med Res Rev. 2020; 40 (3): 1061-1083. doi: 10.1002/med.21648.

17. Gedawy A, Al-Salami H, Dass CR. Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics. Ther Deliv. 2020; 11 (11): 733-753. doi: 10.4155/tde-2020-0102.

18. Davies MJ, Bianchi C, Del Prato S. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors? Metabolism. 2020; 107: 154242. doi: 10.1016/j.metabol.2020.154242.

19. Noor HB, Mou NA, Salem L, Shimul MFA, Biswas S, Akther R et al. Anti-inflammatory Property of AMP-activated protein kinase. Antiinflamm Antiallergy Agents Med Chem. 2020; 19 (1): 2-41. doi: 10.2174/1871523018666190830100022.

20. Rittig N, Aagaard NK, Sundelin E, Villadsen GE, Sandahl TD, Holst JJ et al. Metformin stimulates intestinal glycolysis and lactate release: a single-dose study of metformin in patients with intrahepatic portosystemic stent. Clin Pharmacol Ther. 2021; 110 (5): 1329-1336. doi: 10.1002/cpt.2382.

21. Markowicz-Piasecka M, Sadkowska A, Sikora J, Broncel M, Huttunen KM. Novel sulfonamide-based analogs of metformin exert promising anti-coagulant effects without compromising glucose-lowering activity. Pharmaceuticals (Basel). 2020; 13 (10): 323. doi: 10.3390/ph13100323.

22. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi-Ankrah B et al. Arterial hypertension in women: state of the art and knowledge gaps. Hypertension. 2023; 80 (6): 1140-1149. doi: 10.1161/hypertensionaha.122.20448.

23. Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One. 2014; 9 (3): e91111.

24. Feng W, Gao C, Bi Y, Wu M, Li P, Shen S et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017; 9 (8): 800-809. doi: 10.1111/1753-0407.12555.

25. Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021; 15 (6): 827-840. doi: 10.5009/gnl20367.

26. Green CJ, Marjot T, Tomlinson JW, Hodson L. Of mice and men: is there a future for metformin in the treatment of hepatic steatosis? Diabetes Obes Metab. 2019; 21 (4): 749-760. doi: 10.1111/dom.13592.

27. Huang KH, Lee CH, Cheng YD, Gau SY, Tsai TH, Chung NJ et al. Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. Front Endocrinol (Lausanne). 2022; 13: 1027484. doi: 10.3389/fendo.2022.1027484.

28. Yang MH, Li WY, Wu CF, Lee YC, Chen AY, Tyan YC et al. Reversal of high-fat diet-induced non-alcoholic fatty liver disease by metformin combined with PGG, an inducer of glycine N-methyltransferase. Int J Mol Sci. 2022; 23 (17): 10072. doi: 10.3390/ijms231710072.

29. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013; 1 (1): 57-64. doi: 10.3892/br.2012.18.

30. Gilca-Blanariu GE, Budur DS, Mitrica DE, Gologan E, Timofte O, Balan GG et al. Advances in noninvasive biomarkers for nonalcoholic fatty liver disease. Metabolites. 2023; 13 (11): 1115. doi: 10.3390/metabo13111115.